Poyurovsky M, Weizman A (iunie 2020). „Treatment of Antipsychotic-Induced Akathisia: Role of Serotonin 5-HT2a Receptor Antagonists”. Drugs (Review). 80 (9): 871–882. doi:10.1007/s40265-020-01312-0. PMID32385739.
Laoutidis, ZG; Luckhaus, C (mai 2014). „5-HT2A receptor antagonists for the treatment of neuroleptic-induced akathisia: a systematic review and meta-analysis”. The International Journal of Neuropsychopharmacology (Review). 17 (5): 823–32. doi:10.1017/S1461145713001417. PMID24286228.
Lohr, JB; Eidt, CA; Abdulrazzaq Alfaraj, A; Soliman, MA (decembrie 2015). „The clinical challenges of akathisia”. CNS Spectrums (Review). 20 Suppl 1: 1–14; quiz 15–6. doi:10.1017/S1092852915000838. PMID26683525.
Poyurovsky M, Weizman A (iunie 2020). „Treatment of Antipsychotic-Induced Akathisia: Role of Serotonin 5-HT2a Receptor Antagonists”. Drugs (Review). 80 (9): 871–882. doi:10.1007/s40265-020-01312-0. PMID32385739.
Laoutidis, ZG; Luckhaus, C (mai 2014). „5-HT2A receptor antagonists for the treatment of neuroleptic-induced akathisia: a systematic review and meta-analysis”. The International Journal of Neuropsychopharmacology (Review). 17 (5): 823–32. doi:10.1017/S1461145713001417. PMID24286228.
Lohr, JB; Eidt, CA; Abdulrazzaq Alfaraj, A; Soliman, MA (decembrie 2015). „The clinical challenges of akathisia”. CNS Spectrums (Review). 20 Suppl 1: 1–14; quiz 15–6. doi:10.1017/S1092852915000838. PMID26683525.